Head-To-Head Analysis: NeurAxis (NRXS) & Its Peers

NeurAxis (NASDAQ:NRXS) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare NeurAxis to related businesses based on the strength of its institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Insider and Institutional Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 21.1% of NeurAxis shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NeurAxis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
NeurAxis Competitors	-300.62%	-179.55%	-22.71%

Analyst Recommendations

This is a summary of current ratings and price targets for NeurAxis and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	1	1	0	2.50
NeurAxis Competitors	4309	10596	18377	837	2.46

NeurAxis presently has a consensus price target of $13.00, indicating a potential upside of 139.85%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.26%. Given NeurAxis’ stronger consensus rating and higher probable upside, research analysts clearly believe NeurAxis is more favorable than its competitors.

Volatility & Risk

NeurAxis has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, NeurAxis’ competitors have a beta of 5.41, indicating that their average stock price is 441% more volatile than the S&P 500.

Valuation and Earnings

This table compares NeurAxis and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NeurAxis	$6.53 million	-$14.63 million	-5.11
NeurAxis Competitors	$1.89 billion	$136.85 million	6.01

NeurAxis’ competitors have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

NeurAxis competitors beat NeurAxis on 9 of the 13 factors compared.

About NeurAxis

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.